In this study differences in prostate cancer related functional outcomes between symptomatic and PSA-detected survivors are investigated as part of the Life After Prostate Cancer Diagnosis (LAPCD) study [21], a population based study of over 35,000 men diagnosed with prostate cancer 18-42 months previously, the results of which have been previously reported for specific stage and treatment types [12]. The gene discussed is KLK3; the disease is Familial prostate cancer.